Navigation Links
Vical to Present at UBS Global Life Sciences Conference

NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- The Vical Incorporated (Nasdaq: VICL) presentation at the UBS Global Life Sciences Conference on Monday, September 22, at 1 p.m. Eastern Daylight Time, will be available by live and archived webcast through the Events page at

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127


SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
2. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
3. Vical to Present at Upcoming Investor Conferences
4. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
5. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
6. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
7. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
8. Vical to Present at Cowen and Company Health Care Conference
9. Vical to Present at BIO and BVGH Global Health Partnering Event
10. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
11. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
Post Your Comments:
(Date:10/12/2015)... ROSEVILLE, Minn. , Oct. 12, 2015 /PRNewswire/ ... Drug Administration (FDA) has designated its lead Microbiota ... for the treatment of recurrent Clostridium difficile ... gastrointestinal (GI) infection that causes 29,000 deaths in ... clinical stage biotechnology company that was founded to ...
(Date:10/12/2015)... , 12 de octubre de 2015 El ... llegó a un récord en el congreso con su ... de la International Plasma Awareness Week (IPAW), que se ... está patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 2015 offers ... enriched online experience --> ... version for enriched online experience --> ... alternative to print version for enriched online experience ... technical and medical information products and services, announced today ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/7/2015)... October 7, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Washington , former long- term executive at American Express ... --> NXTD ) ("NXT-ID" or the "Company"), a ... market and creator of the Wocket® smart wallet announces ...
Breaking Biology News(10 mins):